Hepatitis B Virus Infection in Human Immunodeficiency Virus Infected Southern African Adults: Occult or Overt--that is the Question

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Oct 11

PMID 23049685

Citations 34

Authors

Trevor G Bell

Euphodia Makondo

Neil A Martinson

Anna Kramvis

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) share transmission routes and are endemic in sub-Saharan Africa. The objective of the present study was to use the Taormina definition of occult HBV infection, together with stringent amplification conditions, to determine the prevalence and characteristics of HBV infection in antiretroviral treatment (ART)-naïve HIV(+ve) adults in a rural cohort in South Africa. The presence of HBV serological markers was determined by enzyme linked immunoassay (ELISA) tests. HBV DNA-positivity was determined by polymerase chain reaction (PCR) of at least two of three different regions of the HBV genome. HBV viral loads were determined by real-time PCR. Liver fibrosis was determined using the aspartate aminotransferase-to-platelet ratio index. Of the 298 participants, 231 (77.5%) showed at least one HBV marker, with 53.7% HBV DNA(-ve) (resolved) and 23.8% HBV DNA(+ve) (current) [8.7% HBsAg(+ve): 15.1% HBsAg(-ve)]. Only the total number of sexual partners distinguished HBV DNA(+ve) and HBV DNA(-ve) participants, implicating sexual transmission of HBV and/or HIV. It is plausible that sexual transmission of HBV and/or HIV may result in a new HBV infection, superinfection and re-activation as a consequence of immunesuppression. Three HBsAg(-ve) HBV DNA(+ve) participants had HBV viral loads <200 IU/ml and were therefore true occult HBV infections. The majority of HBsAg(-ve) HBV DNA(+ve) participants did not differ from HBsAg(+ve) HBV DNA(+ve) (overt) participants in terms of HBV viral loads, ALT levels or frequency of liver fibrosis. Close to a quarter of HIV(+ve) participants were HBV DNA(+ve), of which the majority were HBsAg(-ve) and were only detected using nucleic acid testing. Detection of HBsAg(-ve) HBV DNA(+ve) subjects is advisable considering they were clinically indistinguishable from HBsAg(+ve) HBV DNA(+ve) individuals and should not be overlooked, especially if lamivudine is included in the ART.

Citing Articles

Hepatitis B seroprevalence among HIV-positive adults in the Free State, South Africa.

Muir D, Vawda S, Bester P, van Rooyen C, Goedhals D South Afr J HIV Med. 2025; 26(1):1654.

PMID: 40061112 PMC: 11886558. DOI: 10.4102/sajhivmed.v26i1.1654.

High prevalence of hepatitis B and HIV among women survivors of sexual violence in South Kivu province, eastern Democratic Republic of Congo.

Basimane Bisimwa P, Koyaweda G, Bihehe Masemo D, Ayagirwe R, Birindwa A, Bisimwa P PLoS One. 2024; 19(7):e0292473.

PMID: 38959256 PMC: 11221749. DOI: 10.1371/journal.pone.0292473.

Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review.

Bazie M, Sanou M, Djigma F, Compaore T, Obiri-Yeboah D, Kabamba B World J Hepatol. 2024; 16(5):843-859.

PMID: 38818293 PMC: 11135261. DOI: 10.4254/wjh.v16.i5.843.

Persistence and risk factors of occult hepatitis B virus infections among antiretroviral therapy-naïve people living with HIV in Botswana.

Anderson M, Phinius B, Phakedi B, Mudanga M, Bhebhe L, Tlhabano G Front Microbiol. 2024; 15:1342862.

PMID: 38784816 PMC: 11112038. DOI: 10.3389/fmicb.2024.1342862.

Control of occult hepatitis B virus infection.

Lalana Garces M, Ortiz Pastor O, Sole Enrech G, Guerra-Ruiz A, Casals Mercadal G, Almeria Lafuente A Adv Lab Med. 2023; 3(4):321-341.

PMID: 37363431 PMC: 10197267. DOI: 10.1515/almed-2022-0065.

References

Chu C, Liaw Y . Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2011; 54(1):88-90. DOI: 10.1093/cid/cir755. View

Kramvis A, Kew M . Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res. 2007; 37(s1):S9-S19. DOI: 10.1111/j.1872-034X.2007.00098.x. View

Soriano V, Sheldon J, Ramos B, Nunez M . Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS. 2006; 20(3):451-3. DOI: 10.1097/01.aids.0000200538.25103.3a. View

Lukhwareni A, Burnett R, Selabe S, Mzileni M, Mphahlele M . Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009; 81(3):406-12. DOI: 10.1002/jmv.21418. View

Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P . The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008; 98(7):541-4. PMC: 3008405. View

Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, Saito T . What can be revealed by extending the sensitivity of HBsAg detection to below the present limit?. J Hepatol. 2008; 49(1):17-24. DOI: 10.1016/j.jhep.2008.03.019. View

Makondo E, Bell T, Kramvis A . Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa. PLoS One. 2012; 7(9):e46345. PMC: 3460816. DOI: 10.1371/journal.pone.0046345. View

Firnhaber C, Chen C, Evans D, Maskew M, Schulz D, Reyneke A . Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. Int J Infect Dis. 2012; 16(4):e268-72. DOI: 10.1016/j.ijid.2011.12.007. View

Burnett R, Francois G, Kew M, Leroux-Roels G, Meheus A, Hoosen A . Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 2005; 25(2):201-13. DOI: 10.1111/j.1478-3231.2005.01054.x. View

10.

Raimondo G, Allain J, Brunetto M, Buendia M, Chen D, Colombo M . Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49(4):652-7. DOI: 10.1016/j.jhep.2008.07.014. View

11.

Hoffmann C, Charalambous S, Martin D, Innes C, Churchyard G, Chaisson R . Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008; 47(11):1479-85. PMC: 2670447. DOI: 10.1086/593104. View

12.

Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, Flanigan T . Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther. 2011; 16(7):1057-62. PMC: 3205462. DOI: 10.3851/IMP1872. View

13.

Mayaphi S, Roussow T, Masemola D, Olorunju S, Mphahlele M, Martin D . HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J. 2012; 102(3 Pt 1):157-62. DOI: 10.7196/samj.4944. View

14.

Thomas D . Growing importance of liver disease in HIV-infected persons. Hepatology. 2006; 43(2 Suppl 1):S221-9. DOI: 10.1002/hep.21033. View

15.

Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M . Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion. 2011; 52(4):880-92. DOI: 10.1111/j.1537-2995.2011.03355.x. View

16.

Melegari M, Bruno S, Wands J . Properties of hepatitis B virus pre-S1 deletion mutants. Virology. 1994; 199(2):292-300. DOI: 10.1006/viro.1994.1127. View

17.

Gilson R, Hawkins A, Beecham M, Ross E, Waite J, Briggs M . Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997; 11(5):597-606. DOI: 10.1097/00002030-199705000-00007. View

18.

Chun H, Roediger M, Hullsiek K, Thio C, Agan B, Bradley W . Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2011; 205(2):185-93. PMC: 3244364. DOI: 10.1093/infdis/jir720. View

19.

Chung R . Hepatitis C and B viruses: the new opportunists in HIV infection. Top HIV Med. 2006; 14(2):78-83. View

20.

Mphahlele M, Lukhwareni A, Burnett R, Moropeng L, Ngobeni J . High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2005; 35(1):14-20. DOI: 10.1016/j.jcv.2005.04.003. View